Anti–MCP-1 Antibodies Have no Effect on the Ability of AcSDKP To Inhibit the Activation of Primitive Normal Progenitors in LTC Adherent Layers
| Addition . | % Kill . | |
|---|---|---|
| Primitive BFU-E . | Primitive CFU-GM . | |
| None | 43 ± 5 | 50 ± 4 |
| AcSDKP | 5 ± 5 | 0 ± 4 |
| AcSDKP + anti–MCP-1 | 0 ± 5 | 0 ± 5 |
| AcSDKP + control Ig | 6 ± 5 | 0 ± 9 |
| Addition . | % Kill . | |
|---|---|---|
| Primitive BFU-E . | Primitive CFU-GM . | |
| None | 43 ± 5 | 50 ± 4 |
| AcSDKP | 5 ± 5 | 0 ± 4 |
| AcSDKP + anti–MCP-1 | 0 ± 5 | 0 ± 5 |
| AcSDKP + control Ig | 6 ± 5 | 0 ± 9 |
AcSDKP at 300 ng/mL, anti–MCP-1 antibody at 1.6 μg/mL, and control Ig at 1.6 μg/mL. Results shown are the mean ±SEM from four independent experiments. The effect of adding AcSDKP is highly significant (P < .005), but there is no significant difference between adding AcSDKP with or without anti–MCP-1, or control Ig (P > .2).